Biotricity, Inc.
BTCY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $13,790 | $12,063 | $9,639 | $7,650 |
| % Growth | 14.3% | 25.2% | 26% | – |
| Cost of Goods Sold | $3,226 | $3,707 | $4,197 | $3,080 |
| Gross Profit | $10,564 | $8,356 | $5,442 | $4,570 |
| % Margin | 76.6% | 69.3% | 56.5% | 59.7% |
| R&D Expenses | $2,156 | $2,572 | $3,230 | $2,745 |
| G&A Expenses | $10,858 | $14,613 | $17,622 | $18,562 |
| SG&A Expenses | $10,858 | $14,613 | $17,622 | $18,562 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13,013 | $17,185 | $20,852 | $21,307 |
| Operating Income | -$2,449 | -$8,828 | -$15,410 | -$16,737 |
| % Margin | -17.8% | -73.2% | -159.9% | -218.8% |
| Other Income/Exp. Net | -$5,972 | -$5,266 | -$3,248 | -$12,394 |
| Pre-Tax Income | -$8,421 | -$14,094 | -$18,658 | -$29,130 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,421 | -$14,094 | -$18,658 | -$29,130 |
| % Margin | -61.1% | -116.8% | -193.6% | -380.8% |
| EPS | -0.55 | -1.66 | -2.26 | -3.99 |
| % Growth | 66.9% | 26.5% | 43.4% | – |
| EPS Diluted | -0.55 | -1.66 | -2.26 | -3.99 |
| Weighted Avg Shares Out | 21,525 | 8,992 | 8,660 | 7,575 |
| Weighted Avg Shares Out Dil | 21,525 | 8,992 | 8,660 | 7,575 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $5,202 | $5,192 | $2,583 | $10,570 |
| Depreciation & Amortization | $6 | $6 | $6 | $2 |
| EBITDA | -$3,213 | -$8,897 | -$16,070 | -$18,559 |
| % Margin | -23.3% | -73.7% | -166.7% | -242.6% |